Stryker experienced an 8.8% stock drop on September 8, 2026, wiping out over $10 billion in market value due to ongoing manufacturing problems that were thought resolved. Truist Financial lowered its price target from $340 to $310, reflecting concerns over operational risks. However, Seeking Alpha upgraded Stryker to "Strong Buy," citing strong sales growth, solid demand, and a backlog of equipment orders supporting future earnings growth. Additional risk comes from an investigation into whether Stryker properly disclosed the manufacturing issues, adding uncertainty for investors despite the company's promising growth prospects.
As of Oct 07, 2026 03:04 WIB, Stryker Corporation (SYK) trades on Pluang at USD 278.88, down 2.22% in the last day. The stock holds a market cap of $109.40 billion and an enterprise value of $120.87 billion, with a dividend yield of 1.23%. Despite recent operational concerns, Pluang investors show strong buying interest, with 99% of orders being buys at this time.
Stryker (SYK) has been upgraded to a 'Strong Buy' following a significant price pullback to $275, presenting attractive value compared to its historical valuation. The company shows robust organic sales growth across various regions and segments, dri...
Block & Leviton is investigating Stryker Corporation for potentially violating securities laws by allegedly misrepresenting the status of a manufacturing problem affecting its peripheral vascular business. Stryker's CEO initially claimed the issue wa...
